Here is the design of a clinical trial:

Official Title: Scaling Up: A Multi-Site Trial of e-SBI for Alcohol Use in Pregnancy

Included conditions:
- Fetal Alcohol Spectrum Disorders
- Fetal Alcohol Syndrome
- Fetal Alcohol Effect

Study Armgroups:
- {'label': 'General information', 'type': 'PLACEBO_COMPARATOR', 'description': 'Control', 'interventionNames': ['Other: General information']}
- {'label': 'General information + SMS', 'type': 'EXPERIMENTAL', 'description': 'SMS refers to tailored text messaging.', 'interventionNames': ['Other: General information', 'Behavioral: SMS']}
- {'label': 'Baseline brief intervention', 'type': 'EXPERIMENTAL', 'description': 'Brief technology-delivered intervention for alcohol use during pregnancy', 'interventionNames': ['Behavioral: Baseline brief intervention']}
- {'label': 'Baseline brief intervention + SMS', 'type': 'EXPERIMENTAL', 'description': 'Brief technology-delivered intervention for alcohol use during pregnancy, plus tailored text messaging', 'interventionNames': ['Behavioral: Baseline brief intervention', 'Behavioral: SMS']}
- {'label': 'Baseline brief intervention + 2 booster sessions', 'type': 'EXPERIMENTAL', 'description': "Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (\\<5 minutes) online boosters using the participants' own mobile device.", 'interventionNames': ['Behavioral: Baseline brief intervention', 'Behavioral: Remote online booster sessions']}
- {'label': 'Baseline brief intervention + 2 booster sessions + SMS', 'type': 'EXPERIMENTAL', 'description': "Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (\\<5 minutes) online boosters using the participants' own mobile device, plus tailored SMS.", 'interventionNames': ['Behavioral: Baseline brief intervention', 'Behavioral: Remote online booster sessions', 'Behavioral: SMS']}

Interventions:
- {'type': 'OTHER', 'name': 'General information', 'description': 'General information related to pregnancy is provided electronically.', 'armGroupLabels': ['General information', 'General information + SMS']}
- {'type': 'BEHAVIORAL', 'name': 'Baseline brief intervention', 'description': "Interactive brief motivational intervention is delivered electronically. Provides an introduction, describing the purpose and duration, emphasizing the non-judgmental nature of the brief intervention (BI). Uses a high-quality video featuring gain-framed messaging, quit recommendation, and testimonial from a race-matched woman; tailored on race-ethnicity, efficacy, binge frequency, and level of concern regarding her own alcohol use. The e-BI poses a question regarding the participant's willingness to avoid alcohol throughout her pregnancy. Responses to this question will sort participants into one of three major branches, each using motivational principles to promote alcohol abstinence during pregnancy.", 'armGroupLabels': ['Baseline brief intervention', 'Baseline brief intervention + 2 booster sessions', 'Baseline brief intervention + 2 booster sessions + SMS', 'Baseline brief intervention + SMS']}
- {'type': 'BEHAVIORAL', 'name': 'Remote online booster sessions', 'description': "Two \\< 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.", 'armGroupLabels': ['Baseline brief intervention + 2 booster sessions', 'Baseline brief intervention + 2 booster sessions + SMS']}
- {'type': 'BEHAVIORAL', 'name': 'SMS', 'description': 'Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.', 'armGroupLabels': ['Baseline brief intervention + 2 booster sessions + SMS', 'Baseline brief intervention + SMS', 'General information + SMS']}

Primary Outcomes:
- {'measure': 'Number of participants abstinent from alcohol as measured by Timeline FollowBack Calendar Recall and Ethyl Glucuronide (EtG)', 'description': 'The primary outcome of abstinence will be defined as no self-report of alcohol use in the past 90 days via Timeline FollowBack, and no evidence of use via EtG. The Timeline FollowBack will be administered at 34 weeks gestation and biospecimens for EtG are collected at approximately 37 weeks gestation (36 weeks for fingernails; 38 weeks for toenails).', 'timeFrame': '90 days'}

Please estimate the sample size based on the assumption: 
Type 1 error rate of 0.05, 80% power, and approximately 15% dropout rate.
Sample size determination
        For our primary hypothesis that 90-day alcohol abstinence will be greatest with a single baseline session plus boosters, followed by a single baseline session alone, compared with no BI (BI+booster>BI alone>no intervention), we plan a test for linear trend based on the Mantel-extension test. We also considered a second doseâresponse pattern, that is, a plateau pattern (BI+booster=BI alone and BI with and without booster>no intervention), which would be tested with a one-sided Î§2 test based on isotonic regression and the restricted likelihood ratio statistic.42 A priori power analyses were calculated for Mantel-extension and Ï2 tests using a Monte-Carlo simulation of over 2000 iterations. We estimated that with a type 1 error rate of 0.05, 110 participants per dose level (330 participants in total) would be sufficient to achieve at least 80% power to detect small values (effect size=0.05) of the linear slope (or step values for the plateau pattern). Our proposed sample size is 128 participant per dose level (384 total) to allow for roughly 15% dropout or other unforeseen threats.